Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pmcb now that is worth looking at
CGRA NICE NEWS
You can say that again.
CGRA has huge news out today!!!
CGrowth Capital is Wild for Wildfire's Cannabis License
SILVERDALE, WA / ACCESSWIRE / May 18, 2016 / CGrowth Capital, Inc. (OTC Pink: CGRA) (the "Company") is pleased to announce that Wildfire Cannabis Company ("Wildfire"), the Company's Tier 3 cannabis producing tenant, has successfully passed their Final Inspection with the Washington State Liquor Cannabis Board ("LCB"). With this milestone, Wildfire will now move to finalize Phase I of the development and begin plant production in the days to come. The status change means revenues are imminent for the Company, who will concurrently begin Phase II of the buildout and production with Wildfire to include additional outdoor grow operations.
Robert Foster, Manager/Owner of Wildfire Cannabis Company stated, "We are very appreciative of CGrowth Capital's patience through this tedious process of requirements set forth by Washington State to grow cannabis legally. For CGrowth to have the open minded business savviness of purchasing an old industrial facility and then looking to the future and bringing it new life in such a lucrative way is to be commended. We could not have gotten to this point without them and the future potential for all of us is now unlimited."
The Company previously announced approvals by Stevens County and the state of Washington for the legalized production and processing of cannabis at the Company's Chewelah facility. Based on the current infrastructures and approvals, the Company is working on the initial 90,000 square feet of canopy space and is working towards doubling its capacity during the year for a total of six (6) licensed tenants (there are currently three (3) tenants under contact). Under the Company's turnkey lease terms, the rental potential is in excess of $2,000,000 annually.
About CGrowth Capital, Inc.:
If you are gonna get in SCNP buy on the bid it is up to $3 and no selling!!!!!!!$!!
$AMRS Amyris is revolutionizing the cosmetics industry by providing sustainable, plant sugar-derived ingredients with superior performance. Amyris’s cosmetic products are plant-derived, renewably-sourced and ECOCERT-approved. Our patented technology converts renewable sugarcane into high quality cosmetic ingredients, ensuring supply, price and composition to our customers around the world. We are currently selling two products:
Neossance® Squalane
Neossance® Hemisqualane
Learn more at www.neossance.com
https://amyris.com/products/cosmetics/
SCNP bid increasing and no selling!!!!!! We up to $2.25
BHGI: Looking forward to the court decision on Friday (May 20th) that will ostensibly change the dynamics of this stock.
DIRV .0011 news: DirectView Holdings Enters into Strategic Co Marketing Agreement with TACLENS, LLC – Tactical Law Enforcement Networking Solutions
DirectView to serve as body worn camera solutions provider to TACLENS
NEW YORK, NY -- May 18, 2016 -- InvestorsHub NewsWire -- DirectView Holdings, Inc. (DIRV), a company focused on the ownership and management of leading video and security technology companies, today announced that it has entered into a strategic co marketing agreement with TACLENS, LLC headquartered in Dallas, Texas (the “Agreement”), whereby DirectView Holdings will be engaged as the body worn camera solutions provider for TACLENS clients in the law enforcement community.
Under the terms of the Agreement, TACLENS will recommend, promote and endorse DirectView as its vendor of choice for the planning and deployment of body worn cameras and related services for their clients in law enforcement who are seeking to implement body cameras in their departments. TACLENS has extensive experience in taking a consultative approach to each clients needs and address them accordingly. They have several years of experience in working with situations to assist departments obtain funding and tools to better enhance their law enforcement objectives. They have many clients who have been engaged in the discussion to add body cameras to their police departments and are now becoming active in that space thus forming this new relationship with DirectView. TACLENS has had success in working with law enforcement in consulting, sourcing of funding for projects, hardware deployment and much more.
Mr. Flinn Carrington, Executive Director of TACLENS commented, “This is a very exciting and important partnership for us. We feel and see in the market place the massive need for body cameras nationwide. It is one of the most talked about and desired technology items we hear about when meeting with departments. Our many years of experience and knowledge in assisting departments source funds for needed and desired items gives us a rare advantage over others in our field. We put the DirectView body camera through our own extensive testing before entering into this agreement and were more than happy with all aspects from the technology itself, the excellent clarity, to dealing with the company representatives. We look forward to introducing the DirectView body cameras in a large way to our clients.”
Commenting on behalf of DirectView, Richard Mireles, Business Development Manager. “We are all so happy to make this great announcement. We have been working toward this for quite a while as this is a very specialized purchase for police departments and they have to get it right. I am so pleased that TACLENS has chosen to partner with DirectView after much communication and countless hours of pilot testing. We have the right product at the right time to meet the ever growing demand of police departments nation wide. We are working on establishing many more arraignments like this one with the right partners to help us sell the DirectView body cameras across this great nation of ours.”
$DIRV
$PMCB Scientists have created insulin-producing cells that could replace injections
Australian scientists from the University of Technology, Sydney (UTS), have created a line of insulin-producing cells that could eliminate the need for Type 1 diabetics to inject themselves with insulin.
The development on its own is pretty impressive, but the cells, which are derived from liver cells, are now on their way to being incorporated to a world-first bio-artificial pancreas after being licensed by US biotechnology company PharmaCyte Biotech last October.
PharmaCyte Biotech has already acquired something called the Cell-in-a-Box® system, which is basically a tiny cellulose-based ‘capsule’ that can house artificial cells and integrate them into a human body. This platform can be used to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to, but after acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sites on targeting Type 1 diabetes.
Type 1 diabetes or juvenile-onset diabetes is an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents it from properly regulating the body’s blood glucose levels by releasing insulin.
The new cell line, called “Melligen” cells, is derived from human liver cells, which have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells.
“When a foetus develops, the liver and the pancreas form from the same endodermal origin,” explained Ann Simpson from UTS:Science, who has been developing the cells over the past 20 years, in a press release. Which means that they should have the potential to do the same things as one another.
Early lab trials have shown that the genetically modified Melligen cells are able to release insulin in direct response to the amount of glucose in their surroundings – something that could help type 1 diabetics to live without daily injections and regulate their blood sugar levels naturally.
“My team and I are excited by the prospect of working with PharmaCyte Biotech to eliminate daily injections for insulin-dependent diabetic patients,” said Simpson in the release.
The next step for the company is for PharmaCyte Biotech to embed clusters of the Melligen cells into the Cell-in-a-Box® capsule, which is around the size of a pin head.
These artificial pancreases will then be transplanted into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.
Several other groups are now working on artificial pancreases that use sensors under the skin, or even temporary tattoos to monitor blood glucose levels. But these systems all require a pump to control the amount of insulin required in response to these levels, rather than biologically sensitive cells.
It’s pretty exciting to see all the ground-breaking work on diabetes and insulin-producing cells finally be commercialized into a product that could directly change people’s lives.
—
Learn more here http://austrianova.com/healthcare/
Hearing same thing my friend.
I like it! Tomorrow should be a very good day, I am hearing that there will be a few more players jumping in. Still holding long and strong for me. Look at CGRW if you want to see where CGRA is going, and CGRA is already ahead of the game in everything except pps. Epic correction about to take place.
CGRA-- A pioneer in their FIELD. (pun intended).
$CGRA FIRST EVER OTC COMPANY WITH FINAL APPROVAL TO GROW MJ ON THEIR PROPERTY!
CGRA Facebook MJ update
A big congratulations to Wildfire - they are good to "grow"! Approval received from Washington State Liquor and Cannabis Board.
https://www.facebook.com/CGrowthCapital/posts/1090567284343249
Christmas Came Early, Wildfire Passed Final Inspection, More info to Follow, thx for all the support!
https://twitter.com/fostermrobert/status/732655098162110464
Big BOOM.
$AMRS Amyris Inc. Has a beautiful chart~ Thanks!
HWICQ added to my active watch list. Thanks homeboy.
Good morning Sporty,
HWICQ, keep your eyes on it today, somethings going down over there. It has a super small float and I think it's getting bought up today by a group of investors. L2 is crazy thin to .25 and it's at .0045 currently.
$MCGI Nurses Lounge: A Nurse Recruiter's Greatest Assetl
$PMCB Johnson & Johnson and Big Pharma Could Find a Diabetes "Cure" With PharmaCyte Biotech's Type 1 Diabetes Treatment
Johnson & Johnson (J&J), like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, J&J's head of global innovation, said that his company's recent decision to partner with a privately held San Diego biotech was to "hedge our bets to make sure we would win in this space." Johnson & Johnson's deal with ViaCyte, Inc. is an effort to speed up the development of ViaCyte's stem cell treatment for Type 1 diabetes. Winning in the diabetes space, however, might mean that Johnson & Johnson or another larger company in the biopharmaceutical industry will need to take a long look at PharmaCyte Biotech (OTCQB: PMCB), a small Silver Spring, Maryland firm with its own Type 1 diabetes treatment.
After sitting in on PharmaCyte's second annual International Diabetes Consortium meeting in Vienna, Austria, it was clear that PharmaCyte has a treatment that many other companies, organizations and research institutes have yet to prove they're capable of producing. It is this treatment that Johnson & Johnson and other biopharmaceutical companies should be eyeing very closely. In order to pull off the feat of developing a successful treatment or "cure" for those who are insulin dependent, most researchers are looking for three key ingredients. And PharmaCyte has all three: (1) a cell line capable of producing insulin that can act as an "artificial pancreas," (2) an encapsulation technology that can house the cell line inside the body and keep it protected from the body's immune system, and finally (3) a team of experts in the diabetes arena that can bring the treatment to life.
PharmaCyte's treatment for type 1 diabetes and type 2 insulin-dependent diabetes is an encapsulated human cell line, called the Melligen cell line, which are liver cells that have been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. PharmaCyte will encapsulate the Melligen cells using its signature live-cell encapsulation technology, Cell-in-a-Box®.
Developing a successful diabetes treatment for Type 1 diabetics all starts with a cell line that is capable of producing insulin on demand. Unlike most who have turned to islet cells or stem cells, PharmaCyte has instead turned to Professor Ann Simpson, one of the 17 members on PharmaCyte's international diabetes consortium, and her colleagues at the University of Technology-Sydney in Australia. Professor Simpson and her team conducted numerous tests during the various stages of the development process and studies were carried out to show that Melligen cells secreted insulin in response to physiological concentrations of glucose (blood sugar). Furthermore, when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal. This observation illustrates that Melligen cells can reverse the diabetic condition.
Their work was published in a major research article titled "Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen cells" in the journal Molecular Therapy - Methods & Clinical Development: http://www.nature.com/articles/mtm201511
The authors of the article note that, for the Melligen cells to be effective in treating Type 1 diabetes in humans where the insulin-producing beta cells of the pancreas have been destroyed, it will be necessary to protect these cells from rejection by the body's immune system after they have been introduced into the body. The article points out that one way to protect the Melligen cells would be to encapsulate the cells in protective "cocoons" prior to being placed into a diabetic patient. If this is done, the authors believe that encapsulated Melligen cells may offer a cure for Type 1 diabetes.
Enter step 2 of PharmaCyte Biotech's three-pronged approach, an encapsulation technology capable of protecting the genetically engineered live cells inside. The ability to encapsulate a cell line and keep it protected from immune system attack to treat diabetes has been called the "holy grail" of cell encapsulation. PharmaCyte's live-cell encapsulation technology, Cell-in-a-Box®, appears to be the ideal encapsulation technology for this purpose. In fact, Melligen cells have already been successfully encapsulated using the Cell-in-a-Box® process, and the first preclinical studies have shown that Melligen cells are equally as safe inside the Cell-in-a-Box® capsules as the encapsulated cells that PharmaCyte will be using in its upcoming FDA human clinical trials in advanced pancreatic cancer.
So, with the Melligen cell line in place, and with Cell-in-a-Box® set to house the cell line to keep it protected, the final piece to developing a successful treatment for Type 1 diabetes is a team of experts who can put it all together, test it, modify the treatment where necessary, perfect the dosing in a number of animal models and get the treatment into clinical trials as quickly as possible.
PharmaCyte's CEO, Kenneth L. Waggoner, has assembled 17 experts in the field of diabetes from all over the globe. This group makes up PharmaCyte's International Diabetes Consortium. They have all come together to work toward one goal -- developing an "artificial pancreas" or a "cure" for insulin dependent diabetes. All of these experts are working at the same time in their specific area of expertise rather than waiting for each experiment to run its course before moving on to the next group of experts. It is this approach that should expedite PharmaCyte's path to human clinical trials. PharmaCyte's approach should provide answers more quickly for those larger biopharmaceuticals that expect to win the race to the first truly long-term successful type 1 diabetes treatment.
About Stock Market Media Group
Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. This article was written based upon publicly available information. PharmaCyte Biotech has not endorsed this article, and Stock Market Media Group was not compensated for its production.
Stock Market Media Group may from time to time include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: www.sec.gov, where you can also find all of PMCB's filings and disclosures. We also recommend, as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.
We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about any of the companies we write about are not a recommendation to buy or sell a security.
For more information: www.stockmarketmediagroup.com.
HWICQ has just 30k shares left before .25 ....$500 could become $5000 really fast on HWICQ !
AROPQ great news might be coming on May 23rd:
Aéropostale and key supplier reach deal to settle feud
http://www.bizjournals.com/newyork/news/2016/05/13/aeropostale-mgf-sourcing-supplier-make-deal.html
$AROPQ
CGRA up 33%! Wildfire gets final inspection on MJ build-out on Wednesday, then their MJ license will be active and they can start growing.
$DCAC NEWS out!!!
Event Updates To Shareholders
May 16, 2016
OTC Disclosure & News Service
New York, New York -
Daniels Corporate Advisory Company, Inc - Update To Shareholders.
May 16 2016.
New York, New York:
Daniels Corporate Advisory Company Inc. (OTC:QB "DCAC") is pleased to announce to those shareholders that have weathered our storms with us that the Convertible Preferred Stock Anti-Dilutive dividend is still on the boards. We are in the formal filing cycle for capitalization additions/changes needing approval from FINRA. We filed our application on March 7, 2016 and correspond regularly with their representative that is handling our request. We have fulfilled all their requests and do not believe it will be much longer. This dividend will be honored in some fashion. There are no problems or hold-ups on our part, the filing cycle with FINRA has been extended, in general, because of all the applicants. We have to wait our turn.
Current Deals:
We are working on several significant deals/projects that will mean the fold-in of a material amount of assets and their corresponding earnings in the near future. Preliminary agreement stage has been reached and a due diligence process is being conducted prior to formal contract signing. These two potential deals/expansion projects have the potential to give DCAC the critical mass to be considered for uplifting and listing on a Major Stock Exchange. Because of the need for one year of certified statements as a collective unit is necessary to meet the filing requirements of a Major Exchange it is going to take 18 - 24 months for all these events to occur and for DCAC to uplift
The listing on a major exchange will give DCAC the credibility necessary to attract long term investors, those institutions interested in developing companies and not in just trading common stock. Venture Capital and Private Equity Firm want to see a liquid exit strategy from the start of their investment and will see it in DCAC with our major exchange listing.
The DCAC major exchange listing will allow each incubated subsidiary deal to raise initial capital on its parent's common stock and to eventually be an independent public company on its own. The shareholder base of DCAC will be receiving value in each one of these IPO or Alternate Public Offerings.
These two potential projects will be merger/acquisitions into two separate subsidiaries of DCAC, incubated and then brought public as independent companies within a two year period. DCAC is their Corporate Strategy Advisory and will remain the parent company with all merger/acquisition deals, being developed/expanded by Daniels, conducted in subsidiaries. While projects may be changed or be altered because of due diligence findings, the model is intact and will be proven with the best candidates possible.
We will be keeping shareholders up to date on a regular basis. We hope you have the patience to continue with us.
Safe Harbor Statement: This press release contains forward-looking statements, including expected industry patterns and other financial and business results that involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Actual results may differ materially from those contained in the forward-looking statements in this press release. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.
Arthur D. Viola, Chairman & CEO. onewallstreetn@aol.com .
Copyright © 2016 OTC Markets. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
This week: ARCS ONCI PPPI BHGI top of the list. FDIT sleeper very small float most available shares were transferred to preferred. Moves easily business to business awareness software pulling in current subscription revenues.
Good Morning SPORT REPORT members:
Playing a variety of stocks this week:
ONCI--Looking for rumored news to come out either later today or tomorrow.
CCTL--Looking also for possible news, and a move to higher grounds.
BHGI--Waiting for the dust to settle, then capitalize on way oversold shares.
ASUV--Awaiting the official merger with Klean Industries, could be anytime.
JNSH--Small position there based upon court case scheduled for tomorrow.
EEGI--Looking for a break above .002, then see where she goes and how she looks.
Might be forgetting one, but it is early.
LET'S MAKE THIS A PROFITABLE WEEK.
Best regards,
SPORTYNORTY
CDNL: CEO bought Shares last week, I think this will go really huge$$$
Hello Clutch,
Long time my friend. DDAY is in a very competitive and up and coming business segment, one i am very familiar with, Fantasy Sports. The two behemoths in the arena are Fan Duels and Draft Kings. They have garnered the largest percentage of market share and have licensing / partnership deals with MLB and the NFL. Carzy Gabey I am familiar with and it appears he is affiliated with DDAY, which is a big positive. I think their business model can succeed, but will be uphill against the two aforementioned behemoths. If DDAY can carve out a niche, they would likely be acquired by one of the two, at a hefty premium. I will definitely add them to my watch list, as i have a pre-disposition to that business model and believe it could be a profitable trade under a myriad of circumstances.
Thanks for the heads up.
SPORTY
$PMCB PharmaCyte’s Novel Diabetes Treatment Approach Could Prove Superior to Other Methods Under Development
Forecasts for the number of people that will be diagnosed with diabetes in the coming years are staggering. While many treatments exist to treat some of the effects of diabetes on patients afflicted with the disease, a “holy grail” to truly treat the disease has yet to be developed. Clearly, an out of the box approach is required. If future test results affirm the data derived from recent studies, the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® diabetes treatment platform could emerge as the treatment of choice for this disease.
Dozens of studies and trials to treat Type 1 and Type 2 diabetes are ongoing, given that the size of the global diabetes market for therapeutic devices and drugs is expected to reach US $114.3 billion by 2018, according to a report by Transparency Market Research. However, since results have been mixed for even the largest and most successful companies, industry participants are now exploring new ideas and new approaches that have demonstrated efficacy in early studies, which could serve as an indirect or direct benefit to PharmaCyte.
For example, one of the top two players in diabetes treatment, Novo Nordisk (NYSE – NVO), announced that it is collaborating with IBM (NYSE – IBM) to combine IBM’s cognitive computing capabilities with diabetes research by collecting and analyzing real-time data from patients using Novo Nordisk treatments and devices. The hope is that this venture leads to improved solutions for diabetes management. Novo Nordisk also submitted a new type of fast-acting mealtime insulin to the FDA for approval, a departure from its primary offerings. Meanwhile, Novo Nordisk competitor Eli Lilly (NYSE – LLY), which has had six diabetes treatments approved since 2014 halted development of a promising diabetes treatment under development. If a company with 6 approved drugs in a treatment category is still working on the problem, and another leader is moving outside of its comfort zone in an effort to develop the most effective therapy available, it is an indication that the time is now for PharmaCyte.
The Company has the exclusive worldwide rights to use Melligen cells to treat diabetes. Melligen cells are genetically engineered from human liver cells and have been shown to secrete insulin in response to the concentrations of glucose (blood sugar) in their environment. A recent article published in scientific journal Molecular Therapy noted that when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal.
This observation illustrates that Melligen cells can reverse the diabetic condition. PharmaCyte plans to encapsulate a human cell line that has been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. Therefore, the Melligen cell line, when combined with Cell-in-a-Box® encapsulation, could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes and Type 2 insulin-dependent diabetes and could potentially replace them. As a result, we look for these shares to move toward the $0.20 level in early 2016.
$GFOX Grey Fox Holdings Corp Gives an Update for Shareholders
Source: InvestorsHub NewsWire
Grey Fox Holdings Corp Gives an Update for Shareholders
ORLANDO, FL -- May 13th, 2016 -- InvestorsHub NewsWire -- Grey Fox Holdings Corporation (OTCQB;GFOX) announces that the Ribbon Cutting Ceremony with Daytona Beachs Chamber of Commerce was a success. The Chamber of Commerce along with Daytona Beach City Officials and local residents in the area were present for the Ribbon Cutting for the Graffiti Junktion Daytona Beach. There was a wide variety of food and drinks these items were from the Graffiti Junktion menu. Daniel Sobolewski stated It was a pleasure meeting everyone that came out to the event and at the same time I was overwhelmed by the turnout. Everyone was extremely impressed with the food and the layout of the restaurant. We were not only able to just impress them but make an impression so they will come back and also refer the restaurant to their friends and family. Also on Saturday May 14th we are one of the participants in the 12th Annual Crawfish Seafood Festival that is happening right on Main St in Daytona Beach. This is a giant block party for the street.
I would also like to add that our attorney has submitted everything with FINRA for the name change and we are currently awaiting on the date the name will officially be changed. Once this happens we will notify our shareholders.
For more information on Grey Fox Holdings Corp or Graffiti Junktion please visit www.greyfoxholdings.com or www.graffitijunktion.com
FORWARD LOOKING STATEMENT
This news release includes forward-looking statements that reflect Grey Fox Holdings Corp, Inc.'s current expectations about its future results, performance, prospects and opportunities. Grey Fox Holding, Corp. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "should," "typical," "we are confident" or similar expressions. These forward-looking statements are based on information currently available to Grey Fox Holdings, Corp. and are subject to a number of risks, uncertainties and other factors that could cause the Company's actual results, performance, prospects of opportunities in the remainder of 2013 and beyond, to differ materially from those expressed in, or implied by, these forward-looking statements.
Contact:
Daniel Sobolewski
CEO
407-415-0013
$SMAA - oo1 // press watch Bouncer / thin l2
New Company direction and a top Notch new CEO with roots in energy.
Hearing possible news as soon as this week per bman!
smaa
http://www.smaalliance.net/energy.html
rawlemon
windstax
WindStax® systems can be tied directly to the utility power to offset your cost of electricity. WindStax can also store electricity... The generators store up to several days of green energy using an advanced power management system. The electricity is 115V or 220V AC or 12/24/48V DC.
windstax Racing - https://s.yimg.com/fz/api/res/1.2/NtsKpISJMMzv5biAkwFIzQ--/YXBwaWQ9c3JjaGRkO2g9MTA4MDtxPTk1O3c9MTkyMA--/http://i1.ytimg.com/vi/CuIiHaxqHQw/maxresdefault.jpg
small ss
thin - clean Level 2
SMAA
$GCEI ON HIGH ALERT> http://www.rewmag.com/article/global-clean-energy-consolidates/
In case you guys missed it.
STOCK IS EXTREMELY UNDERVALUED IMHO!
Go GREEN with Global Clean Energy a Enviromentally Friendly Waste 2 Fuel & PGM (Platinum-Group-Metals) Auto Catalysts Recovery Company.
http://www.globalcleanenergy.net/
glta
Hey Sporty...hope you are doing well. Would you mind checking out $DDAY? There is a DD package put together on the $DDAY board... It's owned by BILLIONAIRE Robert Sillerman. He took GWAY 25,000% a few years ago. $DDAY is partially owned by $MGT. The CEO of $MGT is John McAfee, the great cyber security BILLIONAIRE. Have a great weekend!
$MCGI Letter to Shareholders
Dear Fellow Shareholders:
I am writing to summarize in a little more detail the value proposition of our Nurses Lounge Network, background on myself, history of our network as well as some basic information about our operations.
Why a Professional Network for Nurses?
As a nurse, nursing organization or investor I believe the first question that needs to be answered is what is the value proposition of the business or “why a professional network for nurses?”
The nursing profession can be described as a large inefficient market place made up of thousands of stakeholder organizations with static web sites scattered across the Internet. All needing to maintain communications on various levels with approximately 3 million nursing professionals concerning services, jobs, and educational opportunities to just name a few.
By uniting the nursing profession onto an organized and simple to use communications platform based off of today’s networking technology we are able to create a functional and efficient market-place that benefits each nurse and organization alike.
From an organization’s standpoint, by uniting the profession onto one network:
Nursing Schools benefit by building strong alumni programs and reducing costs and time to fill educational programs.
Nurse Associations can recruit new members and fill CE courses in less time for less money.
Employer’s benefit by reducing hiring costs by reducing time to source and hire new employees.
A supplemental, just-in-time workforce can be developed more efficiently and at substantially lower costs by the ability to communicate opportunities direct to the local workforce while saving hospitals millions of dollars in the process.
As a member of a professional network for nurses, nurses are better able to manage their career by:
Developing and maintaining an online professional profile separate from their social profile.
Create and maintain a professional network of colleagues that can assist each other throughout their careers.
Have access to and apply to more job opportunities with ability to manage their careers throughout their work life.
Maintain open communications with the organizations important to their careers such as employers, local associations and schools offering greater educational opportunities.
Background
As the Founder and President of the Nurses Lounge, I think it would also be helpful to provide a little more background on myself as well as the history of the Nurses Lounge.
I began my business career as an auditor for what is now Ernst and Young and, after a two-year stint, went into doing real estate workouts in the mid-eighties. In the late eighties I started helping a friend do career fairs and eventually started a career fair company of my own and successfully created events for engineering, high-tech and even nursing professions.
In early 90’s I looked at moving high-tech career fairs online first as a bulletin board (on a 486 Dell computer with four 9600 baud modems in a closet) and then to the Internet. In late 90’s we were able to purchase the URL jobs.com for $250k and laundry list of benefits (original asking price was $3 million). After raising near $100 million in funding (60 million from CBS in the form of advertising credits) jobs.com became one of the top 5 job boards.
In May of 2000, with sales just under $1 million dollars for the month and disagreements with the BOD, I left jobs.com. In the next 12 months, sales declined considerably under new management and instead of an IPO the company was sold to what is now Monster.com.
In 2002 I took over the web portal NursesLounge.com and launched a direct mail monthly magazine reporting on the local DFW nursing profession that was mailed to approximately 35k nurses in the Dallas Fort Worth area. Advertisers were mostly hospitals advertising their RN openings. The magazine, combined with the web site, was very successful and by end of 2008 we had another profitable magazine in Chicago as well. There was considerable amount of entrenched competition in each market that we were able to overcome with a better business model based on pricing and content.
By this time, Social Media, primarily Facebook and LinkedIn, had captured the imagination of the public. In our opinion however, neither met the unique needs of the nursing profession and, after finding a third party social platform, we re-launched our web site as a professional network for nurses in the DFW market.
Looking back, we were definitely an early entrant into the market. Most of our target market (nursing schools, associations and hospitals) were still trying to figure out the benefits of having a Facebook page or a presence on LinkedIn.
Additionally, shortly after launch, our platform provider was purchased by a large tech company and began re-purposing the technology for other services. That company was then purchased by Oracle who continued to move the service away from social media.
In the summer of 2014 we found an open source social networking technology, Elgg, along with an experienced development team and re-built our network from the ground-up based on what was needed to provide the nursing profession a resource that would benefit nursing professionals and major stakeholder organizations as well. (We define stakeholders as nursing schools (primarily 4-year schools offering bachelor degrees and graduate level degrees), associations as well as major nurse employers.
The Network
Today the Nurses Lounge consists of a directory of "Interactive Lounges" created for 600 BSN Schools, 6,400 medical facilities, 50 states and 97 Nurse Specialties. During the registration process, a nurse indicates the state of residence, schools attended, employer and specialties and becomes a "follower" of those lounges.
Representatives from schools and medical facilities can claim their interactive Lounge’s and take administrative control. This allows them to post news and information in their ‘lounge’ and immediately sends an alert to their followers. As such, nurses no longer will have to search numerous web sites for basic news and information important to their career.
Like all major networks we do not charge organizations to have an active presence on our network. We generate revenue from advertising with the largest revenue stream expected to come from:
Hospitals posting jobs
Targeted email campaigns
Continuing Education
Supplemental Staffing
Revenues / Costs
With today’s technology, the monthly cost of operating a network with a potential user base of under four million users (100% of target market) is minimal. Additionally, because the only transaction costs are sales costs such as commissions, we project operating costs (before commissions) to top out expense wise over the next 2-3 years in the $1.5 to $2 million range including $500k to $750k marketing and advertising costs (compared to near zero today). That is expected to be true no matter should we do $5 million in sales or $30 million.
Business Points
Major business points we believe to be descriptive of our business model include:
Winner take all business / First Mover Advantage
Growth via Network Effect / Minimal Marketing Costs
Sustainable Competitive Advantage
High Customer Switching Cost
Scalable Business Model (Each new dollar of revenue has a higher margin than the previous dollar)
Excellent Acquisition Candidate
Outlook
Over the near thirty years I have been in the recruitment business, no matter whether it was starting career fairs for a different profession, building a job board or launching a magazine, the same basic questions needed to be answered prior to driving income and reaching profitability.
With that said, I am happy to report that we can now visibly demonstrate to all stakeholder organizations, the benefits of uniting the nursing profession onto one network. As such, we see a clear path to reaching profitability based off of recent sales (all be it at a discounted early adopter price) from health systems in California to New York and South Dakota to Texas.
While there is still plenty of work to be done, I hope the above sheds a little more light on where we came from, what we are building, and where we are at now on our road to maximize shareholder value.
Tim Armes
President and CEO
April 14, 2016
Forward-Looking Statements
This press release may contain forward-looking statements, including information about management’s view of the Company’s future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause results to differ include but are not limited to, successful performance of internal plans, product or services development and acceptance, the impact of competitive services and pricing, or general economic risks and uncertainties. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The Company takes no obligation to update or correct (i) its own forward-looking statements, except as required by law, or (ii) those prepared by third parties that are not paid for by the Company.
- See more at: http://www.nurseslounge.com/lounge/medcareers/letter-to-shareholders.html#sthash.LitOFYZH.dpuf
$CRQE ~ Cirque Energy Inc. due diligence report
$CRQE recent news/filings
## source: finance.yahoo.com
Tue, 19 Jan 2016 13:35:00 GMT ~ Timing is Crucial, Upside Analysis -- New Research on Cirque Energy, Provision Holding, Alstom and Premier Gold Mines
[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 19, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cirque Energy ...
read full: http://finance.yahoo.com/news/timing-crucial-upside-analysis-research-133500420.html
*********************************************************
Tue, 12 Jan 2016 18:04:23 GMT ~ CIRQUE ENERGY, INC. Financials
read full: http://finance.yahoo.com/q/is?s=crqe
*********************************************************
Wed, 06 Jan 2016 22:23:23 GMT ~ CIRQUE ENERGY, INC. Files SEC form 10-Q, Quarterly Report
read full: http://biz.yahoo.com/e/160106/crqe10-q.html
*********************************************************
Fri, 18 Dec 2015 21:35:41 GMT ~ CIRQUE ENERGY, INC. Files SEC form 10-Q, Quarterly Report
read full: http://biz.yahoo.com/e/151218/crqe10-q.html
*********************************************************
$CRQE charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CRQE company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CRQE/company-info
Ticker: $CRQE
OTC Market Place: OTC Pink Current
CIK code: 0001343979
Company name: Cirque Energy Inc.
Company website: http://www.cirque-energy.com
Incorporated In: FL, USA
Business Description: Cirque Energy, Inc. is a sustainable energy development company focused on distributed generation projects and waste stream optimization. Its projects serve utilities, manufacturing, and institutional clients. The company primarily utilizes an Energy Service Company (ESCO) co-development business model to collaborate with clients to develop solutions for their long-term energy needs, using appropriate technologies to optimize energy cost savings.
$CRQE share structure
## source: otcmarkets.com
Market Value: $133,661 a/o Feb 02, 2016
Shares Outstanding: 342,719,443 a/o Jan 06, 2016
Float: 300,000,000 a/o Oct 20, 2015
Authorized Shares: 900,000,000 a/o Oct 20, 2015
Par Value: No Par Value
$CRQE extra dd links
Company name: Cirque Energy Inc.
Company website: http://www.cirque-energy.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CRQE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CRQE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CRQE+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CRQE/news - http://finance.yahoo.com/q/h?s=CRQE+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CRQE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CRQE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CRQE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CRQE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Cirque+Energy+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Cirque+Energy+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Cirque+Energy+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.cirque-energy.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.cirque-energy.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.cirque-energy.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CRQE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001343979&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CRQE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CRQE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CRQE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CRQE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CRQE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CRQE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CRQE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CRQE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CRQE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CRQE+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CRQE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CRQE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CRQE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CRQE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CRQE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CRQE/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CRQE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CRQE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CRQE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CRQE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CRQE
$HNSS Healthnostics, Inc., Announces New BakedTV Developments
Company Projects Focused on Monetization Initiatives Radio Personality Reel Rose to Host Lets Be Blunt
WASHINGTON, DC--(Marketwired - Apr 7, 2016) - Healthnostics, Inc. (OTC PINK: HNSS) is pleased to announce that BakedTV has implemented several new channels focused on revenue generating projects. Significantly, BakedTV has partnered with Amsterdam Trips (www.amsterdamtrips.com), the #1 source for cannabis travel in the US and beyond. Other developments include a new merchandise store which is now open and creation of a new apparel line that will be available soon.
Further, BakedTV is excited to announce that Reel Rose, a New York based radio personality has signed on as host of "Lets Be Blunt," BakedTV's Talk Show discussing all things cannabis. Reel Rose is a radio host, actor, model and a highly regarded inspirational speaker.
Lets Be Blunt will host today's top celebrities, from the music, entertainment, film and television industry that have anything to say about Cannabis today. The show will be about talking and celebrating "All Things Cannabis."
Reel Rose and new projects can be seen on BakedTV's You Tube Channel at:
https://www.youtube.com/channel/UCGJyIOAKH_HzVRaocJgvbHw
As previously relayed in prior announcements, the cannabis market, which according to a report published by The ArcView Group, a cannabis industry investment and research firm, the totality of the legal marijuana market could have an overall worth of $11 billion annually by 2019. By contrast, sales in 2015 were estimated at $3.5 billion.
This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.
Contact:
Healthnostics, Inc.
Investor Relations
contact@healthnostics.com
http://finance.yahoo.com/news/healthnostics-inc-announces-bakedtv-developments-120000481.html
$ZMRK Exciting news!
This is the first of the marketing profiles being presented for the national product launch of M@M(R) & CRAYOLA® jewelry lines. Super Bell (La Bell) will host an invitation buyers event of the brands on June 1st & 2nd @ Caesars Palace Hotel, with a follow on main floor show event @ JCK Show Mandalay Bay Convention Center June 3rd through 6th . Super Bell services over 1000 independent retail jewelers
Followers
|
363
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
14043
|
Created
|
04/20/14
|
Type
|
Free
|
Moderators sharky OptimusPrime |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |